This report provides in depth study of “Paediatric Vaccine Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Paediatric Vaccine Market report also provides an in-depth survey of key players in the market organization.
Global Paediatric Vaccine Market overview:
BusinessIndustryReports have new report spread across 96 pages is an overview of the Global Paediatric Vaccine Market Report 2020. The Global Paediatric Vaccine Market is projected to grow at a healthy growth rate from 2020 to 2024 according to new research. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.
Vaccine provides protection against particular diseases by improving immunity. Vaccines are the biological preparations of weakened or killed microorganism, its surface proteins or its toxins. The global paediatric vaccine market is expected to witness a strong growth during the forecast period due to launch of new products in the market. In-depth discussion of global paediatric vaccine market includes past and current trends with future forecast through 2020. Detailed study of market drivers, threats and opportunities would assist corporate professionals in their strategic decisions. The report also proffers detailed geographical segmentation and identifies profitable areas.
On the basis of Product Type, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Pneumococcal, Varicella, Combinations, Poliovirus, Hepatitis. Based on End Users/Applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Age (0-3), Age (3-12), Age Above 12.
The global paediatric vaccine market is expected to grow at a healthy CAGR in next few years. Increase in growth would be primarily attributed to improved understanding of immunology, which has resulted in launch of new vaccines products. Technological breakthrough has led to development of new vaccine class such as DNA vaccines, vector vaccines, intranasal vaccines, mucosal vaccines and others. However, manufacturing complexity and stringent regulatory compliance are the factors that hinder the market growth.
Asia Pacific was a prominent market for Paediatric Vaccines in 2016. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income. Increased spending on home interiors is fuelling the Paediatric Vaccine market in Asia Pacific.
There are several manufacturers of Paediatric Vaccines in Europe and North America. In North America, the demand for Paediatric Vaccines is primarily driven by the residential sector. Improved standards of living and rising usage of Paediatric Vaccines for flooring purpose are anticipated to drive the market in North America.
In Europe, the demand for Paediatric Vaccine is anticipated to be primarily from the commercial sector. Paediatric Vaccines are being employed widely for flooring in commercial complexes, which is estimated be a major factor that is likely to propelling the consistent expansion of the Paediatric Vaccine market in the region.
Some of the major players that operate in the Global Paediatric Vaccine Market are GlaxoSmithCline, Merck, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Eli Lilly, Pfizer, F. Hoffmann-La Roche, Novo Nordisk.
Latest Industry Updates:
Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease. The primary immunogenicity objectives of non-inferiority for the 20 serotypes included in 20vPnC in adults 60 years of age and older at one month after vaccination were met for all serotypes in common with licensed Prevnar 13® (pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and six of the seven additional serotypes when compared to a licensed pneumococcal polysaccharide vaccine (PPSV23); one of the new seven serotypes missed noninferiority criteria by a small margin.1 Secondary immunogenicity objectives for adults 18-59 years old compared to those 60-64 years old met non-inferiority for all 20 serotypes. The safety objectives were met in adults 18 years of age or older demonstrating that the safety and tolerability of 20vPnC were comparable to licensed pneumococcal vaccines. Based on prior discussions with regulators, these data are expected to meet licensure criteria.
“We are encouraged by the results from this study and remain on track to file the adult 20vPnC indication with the FDA by the end of 2020. 20vPnC builds on a well-established and trusted foundation of pneumococcal conjugate experience and science that Pfizer has accumulated for more than 20 years,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “The results from this pivotal study provide evidence that the 20vPnC vaccine is expected to have a comparable safety profile and likely be as effective as Prevnar 13 in helping prevent invasive pneumococcal disease and pneumonia due to the 13 serotypes in Prevnar 13, and also effective against disease due to the seven additional pneumococcal serotypes in adults 18 years of age or older.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of HD Map in these regions, from 2013 to 2024 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America
Table of Contents:
Section 1 Paediatric Vaccine Product Definition
Section 2 Global Paediatric Vaccine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Paediatric Vaccine Shipments
2.2 Global Manufacturer Paediatric Vaccine Business Revenue
2.3 Global Paediatric Vaccine Market Overview
Section 3 Manufacturer Paediatric Vaccine Business Introduction
3.1 GlaxoSmithCline Paediatric Vaccine Business Introduction
3.1.1 GlaxoSmithCline Paediatric Vaccine Shipments, Price, Revenue and Gross profit 2014-2019
3.1.2 GlaxoSmithCline Paediatric Vaccine Business Distribution by Region
3.1.3 GlaxoSmithCline Interview Record
3.1.4 GlaxoSmithCline Paediatric Vaccine Business Profile
3.1.5 GlaxoSmithCline Paediatric Vaccine Product Specification
3.2 Merck Paediatric Vaccine Business Introduction
3.2.1 Merck Paediatric Vaccine Shipments, Price, Revenue and Gross profit 2014-2019
3.2.2 Merck Paediatric Vaccine Business Distribution by Region
3.2.3 Interview Record
3.2.4 Merck Paediatric Vaccine Business Overview
3.2.5 Merck Paediatric Vaccine Product Specification
3.3 Sanofi Paediatric Vaccine Business Introduction
3.3.1 Sanofi Paediatric Vaccine Shipments, Price, Revenue and Gross profit 2014-2019
3.3.2 Sanofi Paediatric Vaccine Business Distribution by Region
3.3.3 Interview Record
3.3.4 Sanofi Paediatric Vaccine Business Overview
3.3.5 Sanofi Paediatric Vaccine Product Specification
3.4 Bristol-Myers Squibb Paediatric Vaccine Business Introduction
3.5 Abbott Laboratories Paediatric Vaccine Business Introduction
3.6 Eli Lilly Paediatric Vaccine Business Introduction